RET and non-small cell lung carcinoma: The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recently accelerated the approval of selpercatinib/LOXO- 292 and pralsetinib/BLU- 667 for adult patients with advanced RET fusion-positive NSCLC, marking significant progress in targeted therapy.